Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries

被引:0
|
作者
Bhawani Bhatnagar
Viktor Dörfler
Jillian MacBryde
机构
[1] University of Strathclyde,Department of Management Science
[2] University of Strathclyde,Innovation and Operations Management
来源
关键词
Open innovation paradox; Patenting; Licensing; Collaboration; M13; L65; L24; O53; O31; O32; O33; O34; O25;
D O I
暂无
中图分类号
学科分类号
摘要
In this paper, we combine evidence from eight Indian pharmaceutical firms with extant literature and global best practices to conceptualize an integrative framework addressing the open innovation paradox (OIP), i.e., the tension between intellectual protection and openness. Firms in developing countries face additional challenges in the adoption of open innovation, such as the prevalence of open science norms, weak technology transfer systems, and mistrust between universities and industry; therefore, they employ open innovation selectively for pharmaceutical research. Prior research has examined the strategies to resolve OIP in the context of developed countries; the integrative framework proposed in this paper describes strategies for resolving the OIP in the context of developing countries. This framework illuminates the coping processes of the case firms and provides guidelines to uplift and accelerate the adoption of open innovation strategies in developing countries’ pharmaceutical sectors, and thus provides value to both theory and praxis.
引用
收藏
页码:2204 / 2248
页数:44
相关论文
共 50 条
  • [1] Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries
    Bhatnagar, Bhawani
    Dorfler, Viktor
    MacBryde, Jillian
    [J]. JOURNAL OF TECHNOLOGY TRANSFER, 2023, 48 (06): : 2204 - 2248
  • [2] The open innovation paradox: knowledge sharing and protection in R&D collaborations
    Bogers, Marcel
    [J]. EUROPEAN JOURNAL OF INNOVATION MANAGEMENT, 2011, 14 (01) : 93 - +
  • [3] Adopting open innovation strategy to empower SMEs in developing countries
    Hailekiros, Gebremichael S.
    Hou Renyong
    Qian, Sun
    [J]. Proceedings of the 2016 International Conference on Engineering and Technology Innovations, 2016, 43 : 81 - 87
  • [4] Open R&D and open innovation: exploring the phenomenon
    Enkel, Ellen
    Gassmann, Oliver
    Chesbrough, Henry
    [J]. R & D MANAGEMENT, 2009, 39 (04) : 311 - 316
  • [5] The future of pharmaceutical R&D: somewhere between open and reverse innovation?
    Talaga, Patrice
    [J]. FUTURE MEDICINAL CHEMISTRY, 2010, 2 (09) : 1399 - 1403
  • [6] Reinventing R&D in an Open Innovation Ecosystem
    Traitler, Helmut
    Watzke, Heribert J.
    Saguy, I. Sam
    [J]. JOURNAL OF FOOD SCIENCE, 2011, 76 (02) : R62 - R68
  • [7] Open innovation and patterns of R&D competition
    Lim, Kwanghui
    Chesbrough, Henry
    Ruan, Yi
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY MANAGEMENT, 2010, 52 (3-4) : 295 - 321
  • [8] Can Open-Source Drug R&D Repower Pharmaceutical Innovation?
    Munos, B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 534 - 536
  • [9] Substitutability in R&D and Open Innovation: Why Competing Firms Face a Paradox of Openness?
    da Silva, Mario A. P. M.
    [J]. JOURNAL OF THE KNOWLEDGE ECONOMY, 2024, 15 (02) : 5204 - 5229
  • [10] Open innovation: A paradigm shift in pharma R&D?
    Schuhmacher, Alexander
    Gassmann, Oliver
    Bieniok, Doria
    Hinder, Markus
    Hartl, Dominik
    [J]. DRUG DISCOVERY TODAY, 2022, 27 (09) : 2395 - 2405